NASDAQ:EYEN
Eyenovia Inc. Stock News
$0.81
+0.0960 (+13.48%)
At Close: May 31, 2024
Eyenovia: Still A Great Long-Term Investment In Ophthalmology
12:43am, Friday, 21'st May 2021
Eyenovia: Still A Great Long-Term Investment In Ophthalmology
Eyenovia's (EYEN) CEO Sean Ianchulev on Q1 2021 Results - Earnings Call Transcript
10:35pm, Wednesday, 12'th May 2021
Eyenovia's (EYEN) CEO Sean Ianchulev on Q1 2021 Results - Earnings Call Transcript
Eyenovia Announces New $25 Million Credit Facility with Silicon Valley Bank
08:30am, Monday, 10'th May 2021
NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, to
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2020 Results - Earnings Call Transcript
10:50pm, Thursday, 25'th Mar 2021
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2020 Results - Earnings Call Transcript
Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results
04:05pm, Thursday, 25'th Mar 2021
Announces MydCombi expected PDUFA date of October 28, 2021
Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis
07:30am, Tuesday, 23'rd Mar 2021
NEW YORK & CHICAGO--(BUSINESS WIRE)-- #MydCombi--Eyenovia has tapped EVERSANA as exclusive distributor of its MydCombi product for pupil dilation in the U.S., pending the product's FDA approval.
NEW YORK--(BUSINESS WIRE)-- #Optejet--Eyenovia's MAP™ fixed-combination pharmaceutical for pupil dilation has been shown to be safe, effective and superior in comparative study.
EYEN Stock Price Increases Over 15% Pre-Market: Why It Happened
08:09am, Tuesday, 02'nd Mar 2021
The stock price of Eyenovia, Inc. (Nasdaq: EYEN) has increased by over 15% pre-market. This is why it happened.
Eyenovia Announces FDA Acceptance of the MydCombi NDA
07:30am, Tuesday, 02'nd Mar 2021
NEW YORK--(BUSINESS WIRE)-- #mydriasis--FDA accepts Eyenovia's NDA for MydCombi, a unique fixed combination pupil dilation agent delivered with the Optejet. PDUFA date is expected 4Q 2021.
Eyenovia to Host Key Opinion Leader Webinar on Presbyopia
08:00am, Tuesday, 16'th Feb 2021
The webinar, “Presbyopia in Focus: Unlocking One of the Biggest Market Opportunities in Ophthalmology,” is scheduled for Monday, February 22, at 1:00pm ET The webinar, “Presbyopia in Focus: Unlo
Circling Back On Eyenovia
10:24am, Sunday, 03'rd Jan 2021
Today, we revisit a promising small ocular biopharma concern called Eyenovia for the first time in almost 18 months. The company continues to advance its pipeline and recently submitted a marketing ap
NEW YORK--(BUSINESS WIRE)-- #FDA--Eyenovia has submitted an NDA to the FDA for MydCombi, a unique fixed combination mydriatic (pupil dilation) agent delivered by the Optejet dispenser.
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q3 2020 Results - Earnings Call Transcript
10:01pm, Tuesday, 10'th Nov 2020
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q3 2020 Results - Earnings Call Transcript
Eyenovia to Report Third Quarter 2020 Results on Tuesday, November 10
08:00am, Thursday, 05'th Nov 2020
Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day
Eyenovia to Present Clinical Study Updates at the American Academy of Optometry Annual Meeting
12:00am, Monday, 05'th Oct 2020
Drs. Siddarth Rathi, April Jasper to present latest analyses and updates from Eyenovia's clinical studies at the American Academy of Optometry 2020
